EP
CRBP icon

Essential Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Essential Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-56
Closed -$708 – 2804
2025
Q3 		$708 Sell
56
-53
-49% -$504 ﹤0.01% 2117
2025
Q2 		$752 Buy
+109
New +$792 ﹤0.01% 1582

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Essential Partners's CRBP Position: Q4 2025 in Review

Essential Partners sold out of Corbus Pharmaceuticals (CRBP) in Q4 2025, closing a stake of 56 shares — an estimated $708 sold.

Essential Partners first reported a position in CRBP in Q2 2025 and held it in 2 quarters. The position peaked at $752 in Q2 2025. 101 funds tracked by Wall St. Rank hold CRBP as of Q4 2025.

  • Essential Partners reported no remaining Corbus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Essential Partners sold 56 Corbus Pharmaceuticals shares in Q4 2025, an estimated $708.
  • Essential Partners first reported a position in Corbus Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Essential Partners's Corbus Pharmaceuticals position peaked at $752 in Q2 2025.
  • 101 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2025.

Based on Essential Partners's 13F filing for Q4 2025, filed 21 May 2026.